CYP2A6 Polymorphisms: Is there a Role for Pharmacogenomics In Preventing Coumarin-Induced Hepatotoxicity in Lymphedema Patients?

• Casley-Smith JR : Pre-ADEC response on adverse drug reactions to coumarin. Lymphoedema Association of Australia, Malvern, Australia (1995).
   Google Scholar
• Felter SP , VassalloJD, CarltonBD, Daston GP:A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem. Toxicol.44 , 462–475 (2006).
   PubMed Web of Science ®Google Scholar
• Farinola N , PillerN: Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema.Lymphat. Res. Biol.3(2) , 81–86 (2005).
   PubMedGoogle Scholar
• Casley-Smith JR : Benzopyrones in the treatment of lymphedema.Int. Angiol.18(1) , 31–41 (1995).
   Google Scholar
• Badger C , PrestonN, SeersK, MortimerP: Benzo-pyrones for reducing and controlling lymphoedema of the limbs (Cochrane Review). In:The Cochrane Library, Issue 3. John Wiley & Sons, Ltd, Chichester, UK (2004).
   Google Scholar
• Twycross R . Drug treatment for lymphoedema. In: Lymphoedema. Twycross R, Jenns K, Todd J (Eds). Ausmed Publications, Melbourne, Australia, 244–270 (2003).
   Google Scholar
• European Food Safety Authority: Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contacts with Food (AFC) on a request from the Commission related to coumarin. Question number EFSA-Q-2003–118. EFSA J.104 , 1–36 (2004).
   Google Scholar
• Loprinzi CL , KuglerJW, SloanJA et al.: Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N. Engl. J. Med.340 , 346–350 (1999).
   PubMed Web of Science ®Google Scholar
• Lake BG : Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment.Food Chem. Toxicol.37 , 423–453 (1999).
   PubMed Web of Science ®Google Scholar
• Zhuo X , GuJ, Zhang Q-Y, Spink DC, Kaminsky LS, Ding X: Biotransformation of coumarin by rodent and human cytochromes P-450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. J. Pharmacol. Exp. Ther.288 , 463–471 (1999).
   PubMed Web of Science ®Google Scholar
• Cottrell S , OliverK, LakeBG, PowellCJ: Strain-specific enhancement or inhibition of coumarin hepatotoxicity in mice following pretreatment with two different liver enzyme-inducing agents.Fundam. Appl. Toxicol.34(1) , 47–55 (1996).
   PubMedGoogle Scholar
• Lake BG , EvansJG, ChapuisF, WaltersDG, PriceRJ: Studies on the disposition, metabolism and hepatotoxicity of coumarin in the rat and Syrian hamster.Food Chem. Toxicol.40(6) , 809–823 (2002).
   PubMed Web of Science ®Google Scholar
• Miles JS , McLarenAW, ForresterLM, GlanceyMJ, LangMA, WolfCA: Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity.Biochem. J.267(2) , 365–371 (1990).
   PubMed Web of Science ®Google Scholar
• Hadidi H , ZahlsenK, IdleJR, CholertonS: A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin.Food Chem. Toxicol.35(9) , 903–907 (1997).
   PubMed Web of Science ®Google Scholar
• Born SL , CaudillD, FliterKL, PurdonMP: Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation.Drug Metab. Dispos.30(5) , 483–487 (2002).
   PubMed Web of Science ®Google Scholar
• Goeger DE , HsieAW, AndersonKE: Co-mutagenicity of coumarin (1,2-benzopyrone) with aflatoxin B1 and human liver S9 in mammalian cells.Food Chem. Toxicol.37 , 581–589 (1999).
   PubMed Web of Science ®Google Scholar
• Desai PB , NallaniSC, SaneRS et al.: Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab. Dispos.30(5) , 608–612 (2002).
   PubMed Web of Science ®Google Scholar
• Hukkanen J , MantylaM, KangasL et al.: Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol. Toxicol.82(2) , 93–97 (1998).
   PubMedGoogle Scholar
• Casley-Smith JR : Response on proposed de-registration of Lodema tablets. Lymphoedema Association of Australia, Malvern, Australia (1999).
   Google Scholar
• Pasanen M , RannalaZ, ToomingA, SotaniemiEA, PelkonenO, RautioA: Hepatitis A impairs the function of human hepatic CYP2A6 in vivo.Toxicology123(3) , 177–184 (1997).
   PubMed Web of Science ®Google Scholar
• Dalekos GN , Obermayer-StraubP, Bartels M et al.: Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. J. Hepatol.39(5) , 800–806 (2003).
   PubMed Web of Science ®Google Scholar
• Mizutani T : PM frequencies of major CYPs in Asians and Caucasians.Drug Metab. Rev.35(2–3) , 99–106 (2003).
   PubMed Web of Science ®Google Scholar
• Raunio H , RautioA, GullstenH, PelkonnenO: Polymorphisms of CYP2A6 and its practical consequences.Br. J. Clin. Pharmacol.52 , 357–363 (2001).
   PubMed Web of Science ®Google Scholar
• Inoue K , YamazakiH, ShimadaT: CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.Arch. Toxicol.73(10–11) , 532–953, (2000).
   PubMed Web of Science ®Google Scholar
• Fernandez-Salguero P , HoffmanSM, CholertonS et al.: A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet.57 , 651–660 (1995).
   PubMed Web of Science ®Google Scholar
• Haberl M , AnwaldB, KleinK et al.: Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet. Genomics15(9) , 609–624 (2005).
   PubMed Web of Science ®Google Scholar
• Nunoya K -I, Yokoi T, Kimura K et al.: A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride 3(SM-12502). Pharmacogenetics8 , 239–249 (1998).
   PubMedGoogle Scholar
• Nunoya K -I, Yokoi T, Kimura K et al.: A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther.289 , 437–442 (1999).
   PubMed Web of Science ®Google Scholar
• Nakajima M , Kwon J-T, Tanaka N et al.: Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. Ther.69 , 72–78 (2001).
   PubMed Web of Science ®Google Scholar
• Kwon J T, Nakajima M, Chai S et al.: Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics11 , 317–323 (2001).
   PubMedGoogle Scholar
• Yoshida R , NakajimaM, WatanabeY, Kwon JT, Yokoi T: Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol.54(5) , 511–517 (2002).
   PubMed Web of Science ®Google Scholar
• Nakajima M , YokoiT: Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.Drug Metab. Pharmacokinet.20(4) , 227–235 (2005).
   PubMedGoogle Scholar
• Oscarson M , McLellanRA, AspV et al.: Characterisation of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat.20 , 275–283 (2002).
   PubMed Web of Science ®Google Scholar
• Van Iersel MLPS , HendersonCJ, Walters DG, Price RJ, Wolf CR, Lake BG: Metabolism of [3–14C] coumarin by human liver microsomes. Xenobiotica24(8) , 795–803 (1994).
   PubMed Web of Science ®Google Scholar
• Sellers EM , KaplanHL, RomachMK, TyndaleRF: Inhibition of CYP2A6 decreases smoking.Clin. Pharmacol. Ther.63 , 153 (2000).
   Google Scholar
• Ingelman-Sundberg M : Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.Trends Pharmacol. Sci.25(4) , 193–200 (2004).
   PubMed Web of Science ®Google Scholar
• Nakajima M , YamagishiS, YamamotoH, YamamotoT, KuroiwaY, YokoiT: Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.Clin. Pharmacol. Ther.67(1) , 57–69 (2000).
   PubMed Web of Science ®Google Scholar
• Nakajima M , YoshidaR, FukamiT, McLeod HL, Yokoi T: Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett.569 , 75–81 (2004).
   PubMed Web of Science ®Google Scholar
• Burian M , FreundensteinJ, TegtmeierM, Naser-HijaziB, Henneicke-von Zepelin HH, Legrum W: Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. Int. J. Clin. Pharmacol. Ther.41(4) , 141–147 (2003).
   PubMed Web of Science ®Google Scholar
• Kiyotani K , YamazakiH, FujiedaM et al.: Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics13(11) , 689–695 (2003).
   PubMedGoogle Scholar
• Pitarque M , von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun.284(2) , 455–460 (2001).
   PubMed Web of Science ®Google Scholar
• Yoshida R , NakajimaM, NishimuraK, TokudomeS, KwonJT, YokoiT: Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.Clin. Pharmacol. Ther.74(1) , 69–76 (2003).
   PubMed Web of Science ®Google Scholar

Websites

• Lymphovenous Canada: Liver toxicity raises doubts about coumarin. www.lymphovenous-canada.ca/benzo.htm
   Google Scholar
• Human Cytochrome P450 Allele Nomenclature Committee www.cypalleles.ki.se/
   Google Scholar
• Roche Diagnostics: The technology behind AmpliChip microarrays. www.roche-diagnostics.com/media/pdf/presskit/final_technology_behind_cyp450.pdf
   Google Scholar